Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties

Enanta Pharmaceuticals

10/08/2026 21:10

Overview
U.S. biotech firm's fiscal Q3 revenue fell and missed analyst expectations
Company posted a wider net loss of $19.5 mln for fiscal Q3
Lower revenue due to decreased royalties from AbbVie's hepatitis C drug sales

Outlook
Company expects cash and marketable securities to fund operations into fiscal 2029
Enanta on track to initiate RESOLVE Phase 2b/3 RSV trial in 4Q 2026
Company expects topline data from EDP-978 Phase 1 trial in 4Q 2026

Result Drivers
LOWER HCV ROYALTIES - Co said revenue decline was primarily due to lower reported hepatitis C drug sales by AbbVie
REDUCED R&D EXPENSES - Co said research and development expenses fell due to decreased clinical trial costs for RSV programs, partly offset by higher immunology program costs
HIGHER INTEREST EXPENSE - Co said interest expense rose due to the increase in forecasted royalty revenue from AbbVie’s net sales of MAVYRET/MAVIRET

Company press release: ID:nBw6gcKjwa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$14.36 mln
$16.8 mln (5 Analysts)
Q3 Loss Per Share
 
$0.67
 
Q3 Net Loss
 
$19.5 mln
 
Q3 Operating Expenses
 
$31.6 mln
 
Q3 Operating Income
 
-$17.24 mln
 
Q3 Pretax Loss
 
$19.47 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 45.2% above its August 7 closing price of $13.77

Reuters Recommended Reads
Aug 10 - Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates
Aug 10 - Tonix Q2 revenue rises sharply on TONMYA launch
Aug 7 - Canada's DRI Healthcare Q2 income rises, helped by  milestone events in royalty portfolio

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)